A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetic Study of Multiple Rising Doses of TAK-137 in Adult Subjects With Attention-Deficit/Hyperactivity Disorder
Phase of Trial: Phase I
Latest Information Update: 15 Jul 2016
Price : $35 *
At a glance
- Drugs TAK 137 (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions
- Sponsors Takeda
- 31 Aug 2018 Biomarkers information updated
- 13 Jan 2015 Status changed from active, no longer recruiting to discontinued, as reported by ClinicalTrials.gov.
- 16 Oct 2014 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.